iBio (IBIO) Operating Margin (2011 - 2025)

iBio (IBIO) posted quarterly Operating Margin of 5951.0% for Q3 2025, down 128.97% quarter-over-quarter from 2599.0% in Q2 2025.

iBio (IBIO) Operating Margin (2011 - 2025) Analysis & Trends

iBio (IBIO) has reported Operating Margin for 15 consecutive years, with 5951.0% the latest figure, recorded in Q3 2025.

In Q3 2025, Operating Margin changed N/A year-over-year to 5951.0%; the TTM figure through Mar 2026 stood at 9653.0% (down 516953.0% YoY), while the FY2025 annual figure was 4650.5%, up 274239.0% from the prior year.
Operating Margin slipped to 5951.0% in Q3 2025 per IBIO's latest filing, from 2599.0% in the prior quarter.
Across five years, Operating Margin topped out at 377.11% in Q1 2022 and bottomed at 10206.0% in Q3 2023.
Historically, Operating Margin has averaged 3597.2% across 5 years, with a median of 2209.5% in 2024.
On a YoY basis, Operating Margin climbed as much as 329176 bps in 2021 and fell as far as 453146 bps in 2021.
iBio's Operating Margin stood at 6220.24% in 2021, then surged by 94 bps to 377.11% in 2022, then slumped by 2606 bps to 10206.0% in 2023, then surged by 78 bps to 2209.5% in 2024, then plunged by 169 bps to 5951.0% in 2025.
Business Quant data shows IBIO's Operating Margin at 5951.0% in Q3 2025, 2599.0% in Q2 2025, and 2209.5% in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Operating Margin (Qtr)
1	Vertex Pharmaceuticals	140.29 Bn	132.43 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	86.58 Bn	78.58 Bn	3.93 Bn	30.15%
3	Argenx Se	65.26 Bn	60.08 Bn	1.37 Bn	32.54%
4	Moderna	61.87 Bn	56.73 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.18 Bn	37.08 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.51 Bn	28.20 Bn	992.69 Mn	17.93%
7	BioNTech SE	28.90 Bn	10.51 Bn	668.28 Mn	-35.57%
8	Insmed	27.46 Bn	26.30 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.24 Bn	26.41 Bn	-	19.75%
10	iBio	176.21 Mn	176.21 Mn	-	-

Download Data